Effectiveness Outcomes
Within the enteric-coated aspirin cohort, the primary effectiveness end point occurred in 297 participants (cumulative incidence at median follow-up 6.6%) in the 81-mg dose group and 246 participants (7.2%) in the 325-mg dose group (adjusted hazard ratio [AHR], 1.13; 95% CI, 0.88-1.45) (